Legal Representation
Attorney
Nancy Sabarra
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 10, 2023 | MAB1 | E | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | Loading... |
| Feb 10, 2023 | ABN1 | O | ABANDONMENT - EXPRESS MAILED | Loading... |
| Feb 9, 2023 | EXAR | I | TEAS EXPRESS ABANDONMENT RECEIVED | Loading... |
| Jan 26, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 26, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 26, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 23, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 11, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 8, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Medical, biological, and pharmaceutical preparations for scientific, research, medical laboratory use, or for the manufacture of pharmaceuticals, namely, preparations containing messenger RNA for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, namely, for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use
Class 005
Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses and respiratory disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes; drug carriers for medical use, namely, lipid nanoparticles for delivering drugs; lipid nanoparticles for drug delivery sold as an integral component of drugs; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
Class 042
Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
Class 044
Medical services; medical information; providing a website featuring medical information
Classification
International Classes
001
005
042
044